New Risk • Mar 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$871k free cash flow). Negative equity (-CA$6.6m). Earnings have declined by 6.6% per year over the past 5 years. Market cap is less than US$10m (CA$13.5m market cap, or US$9.87m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$2.8m revenue, or US$2.0m). Reported Earnings • Feb 01
Third quarter 2026 earnings released: CA$0.009 loss per share (vs CA$0.011 loss in 3Q 2025) Third quarter 2026 results: CA$0.009 loss per share (improved from CA$0.011 loss in 3Q 2025). Revenue: CA$657.1k (up 31% from 3Q 2025). Net loss: CA$1.14m (loss narrowed 16% from 3Q 2025). New Risk • Jan 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.1m free cash flow). Negative equity (-CA$5.9m). Earnings have declined by 6.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Revenue is less than US$5m (CA$2.6m revenue, or US$1.9m). Market cap is less than US$100m (CA$19.0m market cap, or US$13.7m). Reported Earnings • Nov 02
Second quarter 2026 earnings released: EPS: CA$0.01 (vs CA$0.009 loss in 2Q 2025) Second quarter 2026 results: EPS: CA$0.01 (up from CA$0.009 loss in 2Q 2025). Revenue: CA$672.9k (up 30% from 2Q 2025). Net loss: CA$825.5k (loss narrowed 25% from 2Q 2025). New Risk • Jul 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$965k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$965k free cash flow). Negative equity (-CA$5.3m). Earnings have declined by 6.3% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (CA$2.5m revenue, or US$1.8m). Market cap is less than US$100m (CA$25.2m market cap, or US$18.3m). Reported Earnings • Jul 29
First quarter 2026 earnings released: CA$0.006 loss per share (vs CA$0.01 loss in 1Q 2025) First quarter 2026 results: CA$0.006 loss per share (improved from CA$0.01 loss in 1Q 2025). Revenue: CA$782.7k (up 96% from 1Q 2025). Net loss: CA$723.7k (loss narrowed 42% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jun 30
Full year 2025 earnings released: CA$0.043 loss per share (vs CA$0.041 loss in FY 2024) Full year 2025 results: CA$0.043 loss per share (further deteriorated from CA$0.041 loss in FY 2024). Revenue: CA$2.09m (up 104% from FY 2024). Net loss: CA$5.40m (loss widened 26% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Duyuru • Jun 30
Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025 Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025. Duyuru • May 28
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in funding Rapid Dose Therapeutics Corp. announced a equity private placement financing to issue 13,636,364 units at a price of CAD 0.22 per Unit for gross proceeds of CAD 3,000,000.08 on May 27, 2025. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share at a price of CAD 0.34 per Common Share for a term of two (2) years from the date of issuance of such Warrant. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four-month hold from the applicable date of closing. Duyuru • May 27
Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery Technology Rapid Dose Therapeutics Corp. announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips - representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use. While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy. Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences. A Global Opportunity to Support smoking and Vaping Cessation. According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that. Building on Momentum: Partnership with Global Tobacco Leader. These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives. RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters. New Risk • Mar 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$4.1m). Minor Risks Revenue is less than US$5m (CA$1.6m revenue, or US$1.1m). Market cap is less than US$100m (CA$21.8m market cap, or US$15.0m). Duyuru • Feb 19
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in funding Rapid Dose Therapeutics Corp. announced an equity private placement financing to issue 20,833,333 common shares at an issue price of CAD 0.24 per share for gross proceeds of CAD 4,999,999.92 on February 18, 2025. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing. Reported Earnings • Jan 29
Third quarter 2025 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 3Q 2024) Third quarter 2025 results: CA$0.011 loss per share (further deteriorated from CA$0.009 loss in 3Q 2024). Revenue: CA$501.7k (up 115% from 3Q 2024). Net loss: CA$1.36m (loss widened 39% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Duyuru • Dec 11
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding Rapid Dose Therapeutics Corp. announced that an equity private placement financing of 24,000,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 6,000,000 on December 10, 2024. Each Unit will consist of one Common Share and one Common Share Purchase Warrant. Each Warrant will be exercisable for one Common Share for a period of 2 years from the date of issue, at a price of CAD 0.33 per Common Share. Reported Earnings • Nov 01
Second quarter 2025 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2024) Second quarter 2025 results: CA$0.009 loss per share (further deteriorated from CA$0.007 loss in 2Q 2024). Revenue: CA$515.9k (up 46% from 2Q 2024). Net loss: CA$1.10m (loss widened 51% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. New Risk • Jul 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.8m free cash flow). Negative equity (-CA$3.3m). Revenue is less than US$1m (CA$1.2m revenue, or US$852k). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$22.4m market cap, or US$16.2m). Reported Earnings • Jun 30
Full year 2024 earnings released: CA$0.041 loss per share (vs CA$0.037 loss in FY 2023) Full year 2024 results: CA$0.041 loss per share (further deteriorated from CA$0.037 loss in FY 2023). Revenue: CA$1.02m (up 42% from FY 2023). Net loss: CA$4.31m (loss widened 13% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Duyuru • Jun 27
Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024 Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024. Duyuru • Mar 26
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding Rapid Dose Therapeutics Corp. announced a private placement of up to 35,294,117 common shares at a price of CAD 0.17 per common share for gross proceeds of up to CAD 5,999,999.89 on March 25, 2024. The private placement may close in one or more tranches. The securities issued will be subject to a four month hold from the applicable date of closing. Reported Earnings • Jan 30
Third quarter 2024 earnings released: CA$0.009 loss per share (vs CA$0.006 loss in 3Q 2023) Third quarter 2024 results: CA$0.009 loss per share (further deteriorated from CA$0.006 loss in 3Q 2023). Revenue: CA$233.8k (down 24% from 3Q 2023). Net loss: CA$981.1k (loss widened 68% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Duyuru • Jan 20
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in funding Rapid Dose Therapeutics Corp. announced a private placement of 41,176,470 units at a price of CAD 0.17 per unit for the gross proceeds of CAD 7,000,000 on January 19, 2024. Each unit consists of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one common share at a price of CAD 0.20 per common share for a term of two years from the date of issuance of such warrant. The financing may close in one or more tranches. All securities issued on the financing will be subject to a four month hold from the applicable date of closing. As a part of the transaction, the company may pay a cash commission equal to 6% of the aggregate gross proceeds as placement agent fee. The company shall also issue such number of non-transferable agent warrants as is equal to 6% of the number of Units issued to investors in the financing that were introduced to the company by the agent. New Risk • Jan 17
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$524k free cash flow). Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-CA$3.8m). Revenue is less than US$1m (CA$1.1m revenue, or US$826k). Minor Risks Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Market cap is less than US$100m (CA$18.0m market cap, or US$13.3m). Reported Earnings • Oct 31
Second quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in 2Q 2023) Second quarter 2024 results: CA$0.007 loss per share (improved from CA$0.009 loss in 2Q 2023). Revenue: CA$353.2k (up 164% from 2Q 2023). Net loss: CA$730.7k (loss narrowed 20% from 2Q 2023). Duyuru • Sep 23
Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of Directors Rapid Dose Therapeutics Corp. announced the resignation of Andrew Duckman from the Company's board of directors effective September 18, 2023. New Risk • Aug 17
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Negative equity (-CA$3.2m). Revenue is less than US$1m (CA$897k revenue, or US$663k). Market cap is less than US$10m (CA$13.5m market cap, or US$9.95m). Reported Earnings • Jul 31
First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.01 loss in 1Q 2023) First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.01 loss in 1Q 2023). Revenue: CA$240.8k (up 290% from 1Q 2023). Net loss: CA$566.9k (loss narrowed 44% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Reported Earnings • Jun 29
Full year 2023 earnings released: CA$0.037 loss per share (vs CA$0.085 loss in FY 2022) Full year 2023 results: CA$0.037 loss per share (improved from CA$0.085 loss in FY 2022). Revenue: CA$718.3k (down 59% from FY 2022). Net loss: CA$3.81m (loss narrowed 55% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. Duyuru • Jun 03
Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023 Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023. Duyuru • May 11
Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian Market Rapid Dose Therapeutics Corp. has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: LQS™, a Lidocaine thin film to be used professionally as a topical anesthetic application to provide pain free dental treatment and assisting in allowing pain free local anesthetic where injection is required. XyliStrip™, oral dissolving thin film strip, to be used for the treatment of dry mouth and xerostomia. Board Change • May 05
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Mark Upsdell is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • May 27
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in funding Rapid Dose Therapeutics Corp. announced a brokered private placement of 5,000 units at a price of CAD 1,000 per unit for gross proceeds of CAD 5,000,000 on May 27, 2022. Each unit will consist of CAD 1,000 principal amount of unsecured convertible notes and 100 common share purchase warrants. All notes will have a maturity date of 24 months from the closing date and will bear interest from their date of issue at 10.0% per annum, payable quarterly in arrears. A further 2% per annum interest payment will be made annually in cash or in common shares as determined by the company. During the second year of the two-year term of the notes, the company may prepay all or any portion of each of the notes with an early termination fee payable to each noteholder of 1% of the amount of the principal prepayment of the note. The notes will be convertible, at the option of the holders at any time prior to maturity, into common shares at a conversion price of CAD 0.40 per share. Each warrant may be exercised for one common share at a price of CAD 0.40 per share for a term of 24 months from the closing date. All securities issued will be subject to a four month hold from the date of closing. Duyuru • May 26
Rapid Dose Therapeutics Corp. announced a financing transaction Rapid Dose Therapeutics Corp. announced a private placement of unit at an issue price of CAD 0.30 per unit on May 25, 2022. Each unit consists of one common share and one common share purchase warrant which entitles the holder to acquire one common share of the company at CAD 0.40 per share. The Share Purchase Warrants expire twenty-four months from the date of issuance.
On the same date the company issued 506,157 Common Share Units a for proceeds to CAD 151,847 in its first tranche. Board Change • Apr 27
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). Chairman of the Board & CEO Mark Upsdell is the most experienced director on the board, commencing their role in 2017. Independent Director Peter-Thilo Hasler was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Duyuru • Feb 11
Rapid Dose Therapeutics Announces Management Change Rapid Dose Therapeutics Corp. announced a management change in the Company. The Board of Directors provided notice on February 9, 2022 of its intention not to renew Mr. Thomas Bryson’s employment agreement, which expires at the close of business on March 14, 2022. Mr. Bryson joined RDT in March 2021 with the amalgamation of his predecessor company Consolidated Craft Brands Inc. (“CCB”) and assisted in the integration of CCB into RDT within the terms of his one-year employment contract. Mr. Bryson will continue as an employee of RDT until the end of his agreement, but was relieved of all duties and responsibilities as President of RDT at the close of business on February 9, 2022. Reported Earnings • Jan 30
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: CA$0.008 loss per share (down from CA$0.007 loss in 3Q 2021). Revenue: CA$457.7k (up 262% from 3Q 2021). Net loss: CA$790.8k (loss widened 55% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 02
Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 2Q 2021) The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: CA$324.6k (up CA$321.1k from 2Q 2021). Net loss: CA$539.4k (loss widened 22% from 2Q 2021). Reported Earnings • Aug 30
First quarter 2022 earnings released: EPS CA$0.002 (vs CA$0.006 loss in 1Q 2021) First quarter 2022 results: Net income: CA$128.6k (up CA$623.9k from 1Q 2021). Duyuru • Mar 12
Rapid Dose Therapeutics Corp. Signs Production Agreement With OG Laboratories Canada Inc. to Produce Cannabis Vape and CBD From Hemp Products Rapid Dose Therapeutics Corp. announced that it has entered into a product manufacturing and distribution agreement with OG Laboratories Canada Inc., a wholly owned subsidiary of OG Laboratories LLC. (“OG”) headquartered in Deerfield Beach Florida, to manufacture OG’s vape line of products for the Canadian market. OG will license its formulations, processes, certain technology and provide the equipment to RDT in return for service fees based on sales. OG has experienced rapid growth in the United States creating a premium CBD from hemp line of products marketed through its popular website www.oglaboratories.com. OG has been seeking a Canadian partner who shares the same business vision for its products and has the capability to produce for both the cannabis and non-cannabis sectors in the Canadian marketplace. RDT with its cannabis licence and built out production facility in Burlington Ontario is the perfect fit for establishing OG product sales in Canada. OG’s product line adds to RDT’s growing array of products available to consumers through both the cannabis and nutraceutical distribution channels. With the recently announced acquisition of Consolidated Craft Brands, and through its selling shareholder alliances, these channels are expanding rapidly for products like the ‘QuickStrip™’, nutraceuticals, topicals and now the OG product line. Reported Earnings • Feb 01
Third quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.039 loss in 3Q 2020) Third quarter 2021 results: Net loss: CA$511.8k (loss narrowed 83% from 3Q 2020). Duyuru • Jan 12
Rapid Dose Therapeutics Corp. (CNSX:DOSE) entered into a binding letter of intent to acquire 2544737 Ontario Limited for $5 million. Rapid Dose Therapeutics Corp. (CNSX:DOSE) entered into a binding letter of intent to acquire 2544737 Ontario Limited for $5 million on January 11, 2021. Pursuant to the transaction, Rapid Dose is to issue 16,666,667 common share units, each consisting of 1 common share and 1 common share purchase warrant at a deemed price of $0.30 per unit in exchange for 100% of the common shares of 2544737 Ontario Limited. The number of common shares of Rapid Dose to be issued represents, after issuance, approximately 17.12% of the issued and outstanding shares of Rapid Dose on an undiluted basis and approximately 27.53% of Rapid Dose shares on a fully diluted basis after taking into consideration the exercise of all stock options and warrants outstanding after this transaction. The transaction is subject to negotiation of a definitive agreement which will contain terms and conditions of the LOI and other terms and conditions customary for transactions of the nature and magnitude of the transaction, including completion of due diligence investigations and any necessary approvals of regulatory authorities, shareholders, and board of directors. The transaction will also be subject to a negotiated escrow agreement between the parties including timed releases of the units over a period of 11 months. The transaction is expected to be completed on February 15, 2021. Duyuru • Nov 27
Rapid Dose Therapeutics Signs Definitive Agreement to Enable Commercial Production of Ultrapure THC Distillate Using RDT's Novel CBD to THC Conversion Technology Rapid Dose Therapeutics Corp. announced it signed a definitive agreement with ESJ Enterprises, LLC. RDT has licensed ESJ to produce Ultrapure THC (U-THCTM) Delta 9 distillate using the RDT's proprietary CBD to THC conversion technology. In conjunction with the McMaster University research team lead by Drs. James Mcnulty and Alex Nielsen, RDT has developed a process using its Genius Conversion CatalystTM (GCCTM) to transform CBD isolate into THC distillate with a selective Delta 9 or Delta 8 outcome at a rate of 99%. ESJ has worked with RDT to create a scalable process facility that can produce up to 100 kg of Ultrapure THC (U-THCTM) Delta 9 distillate per day. By combining the steady supply of high-quality Isolera Extracts CBD isolate
with the RDT GCC process, an unlimited amount of U-THCTM distillate is possible. Production of the first 400 kg of U-THCTM distillate will be completed in Oklahoma prior to December
15, 2020 to fill a backlog of demand in the state. Continuous production of the Ultrapure THC will commence in Michigan in December 2020 to ensure cannabis processors there can meet their market supply requirements. Duyuru • Oct 05
Rapid Dose Therapeutics Amends Agreement with Aphria to Produce in Burlington, Ontario Facility Rapid Dose Therapeutics Corp. announced it has amended the agreement with Aphria Inc. signed Nov. 1, 2018. The amended agreement enables RDT to produce the QuickStrips at its licensed Burlington facility for Aphria. As part of the amendment, Aphria relinquishes its global exclusive preferred vendor status enabling RDT to enter new markets with other licensed producers. Duyuru • Aug 21
Rapid Dose Therapeutics Corp. to Report Q1, 2021 Results on Sep 13, 2020 Rapid Dose Therapeutics Corp. announced that they will report Q1, 2021 results on Sep 13, 2020 